PXMD [NASD]
PaxMedica, Inc.
Index- P/E- EPS (ttm)-0.28 Insider Own75.70% Shs Outstand11.78M Perf Week29.62%
Market Cap31.75M Forward P/E- EPS next Y- Insider Trans2.26% Shs Float0.75M Perf Month63.74%
Income-3.30M PEG- EPS next Q- Inst Own0.50% Short Float / Ratio32.59% / 0.08 Perf Quarter-45.84%
Sales- P/S- EPS this Y-10.00% Inst Trans- Short Interest0.25M Perf Half Y-
Book/sh0.20 P/B14.00 EPS next Y- ROA-429.40% Target Price- Perf Year-
Cash/sh0.49 P/C5.67 EPS next 5Y- ROE140.10% 52W Range1.36 - 10.48 Perf YTD-42.97%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-73.28% Beta-
Dividend %- Quick Ratio1.70 Sales past 5Y- Gross Margin- 52W Low105.88% ATR0.38
Employees2 Current Ratio1.70 Sales Q/Q- Oper. Margin- RSI (14)62.64 Volatility21.21% 19.13%
OptionableNo Debt/Eq0.08 EPS Q/Q-268.50% Profit Margin- Rel Volume0.38 Prev Close2.70
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume3.09M Price2.80
Recom- SMA2047.74% SMA5028.81% SMA2008.79% Volume1,170,453 Change3.70%
Nov-22-22 08:00AM
Nov-17-22 08:29PM
Nov-15-22 08:00AM
Nov-08-22 08:00AM
Oct-24-22 08:00AM
08:00AM Loading…
Oct-03-22 08:00AM
Aug-26-22 09:50AM
08:00AM
Aug-24-22 03:27PM
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Derby MichaelExecutive ChairmanAug 30Buy5.2595,000498,7507,336,745Sep 01 04:06 PM
TardiMed Sciences LLC10% OwnerAug 30Buy5.2595,000498,7507,336,745Sep 01 04:07 PM